Based on technology by Kaneka’s subsidiary BioMaster (cultivation of autologous adipose-derived stem cells), Cell Port Clinic Yokohama will start breast reconstruction therapy for cancer patients. Studies will follow the new Law on Ensuring the Safety of Regenerative Medicine issued in November 2014.

Kaneka news release, July 31, 2015